Article citationsMore>>
A. L. Cheng, C. H. Hsu, J. K. Lin, M. M. Hsu, Y. F. Ho, T. S. Shen, J. Y. Ko, J. T. Lin, B. R. Lin, W. Ming-Shiang, H. S. Yu, S. H. Jee, G. S. Chen, T. M. Chen, C. A. Chen, M. K. Lai, Y. S. Pu, M. H. Pan, Y. J. Wang, C. C. Tsai and C. Y. Hsieh, “Phase I Clinical Trial of Curcumin, a Chemopreventive Agent, in Patients with High-Risk or Pre-Malignant Lesions,” Anticancer Research, Vol. 21, No. 4B, 2001, pp. 2895-2900.
has been cited by the following article:
-
TITLE:
Synthesis and Anticancer Activity of Mono-Carbonyl Analogues of Curcumin
AUTHORS:
Song Yin, Xing Zheng, Xu Yao, Yuhong Wang, Duanfang Liao
KEYWORDS:
Curcumin; Mono-Carbonyl Analogues; Anticancer Activity; SAR
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.4 No.1,
February
7,
2013
ABSTRACT: Curcumin has been reported to possess multifunctional bioactivities with low toxicity. However, the clinical application of curcumin has been significantly limited by its instability and poor metabolic property. Up to now, multiple approaches are being sought to overcome these limitations to obtaining “super curcumin”, and many analogues of curcumin have been designed and synthesized. In all of those analogues, a series of mono-carbonyl curcumin analogues deleting the β-diketone draw our attention. Since the seven-carbon β-diketone linker in curcumin may be responsible for its instability, the series of mono-carbonyl curcumin analogues deleting the β-diketone may be potential prodrug with improved pharmacokinetic and pharmacodynamic properties. This review just focuses on these more stable mono-carbonyl analogues of curcumin, and shows the new class of active structure by introducing the synthesis and anticancer activity of them.
Related Articles:
-
Casimir Komenan
-
Sopita Khamrod
-
Kan Wu, Laner Wu, Zhenkun Huang, Yong Jiang, Yun Ma
-
Dikima D. Bibelayi, Albert S. Lundemba, Philippe V. Tsalu, Pitchouna I. Kilunga, Jules M. Tshishimbi, Zéphirin G. Yav
-
Du Thanh Hang, Than Thi Thanh Tra, Le Minh Tuan, Geoffrey Peter Savage